Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Genetic changes in pT2 and pT3 prostate cancer detected by comparative genomic hybridization

Prostate Cancer and Prostatic Diseases volume 11, pages 303–310 (2008)Cite this article

Abstract

Prostate-specific antigen (PSA) screening has led to a remarkable increase in prostate cancer cases undergoing operative therapy. Over half of patients with locally advanced cancer (≧pT3) develop rising PSA levels (biochemical failure) within 10 years. It is very difficult to predict which patients will progress rapidly to advanced disease following biochemical failure (BF). Therefore, a more useful prognostic factor is needed to suggest the most appropriate therapies for each patient. To determine chromosomal aberrations, we examined 30 patients with stage pT2 or pT3 primary prostate adenocarcinomas and no metastases (pN0M0) by comparative genomic hybridization (CGH). Laser capture microdissection (LCM) was used to gather cancer cells from frozen prostate specimens. Common chromosomal alterations included losses on 2q23–24, 4q26–28, 6q14–22, 8p12–22 and 13q21–31, as well as gains on 1p32–36, 6p21 and 17q21–22. Losses at 8p12–22 and 13q21–31 were observed more frequently in pT3 than pT2 tumors (P<0.05 and P<0.01, respectively). Losses at 8p12–22 were more frequent in tumors with BF (P<0.05), and those at 13q12–21 were more frequent in tumors with Gleason score (GS) 7 or more than lower GS (P<0.05). These findings suggest that losses of 8p12–22 and 13q21–31 are important determinants of prostate cancer progression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Dijkman GA, Debruyne FM . Epidemiology of prostate cancer. Eur Urol 1996; 30: 281–295.

    Article  CAS  PubMed  Google Scholar 

  2. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT . Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol 2002; 167: 528–534.

    Article  PubMed  Google Scholar 

  3. Mattfeldt T, Kestler HA, Hautmann R, Gottfried HW . Prediction of prostatic cancer progression after radical prostatectomy using artificial neural networks: a feasibility study. BJU Int 1999; 84: 316–323.

    Article  CAS  PubMed  Google Scholar 

  4. Ichikawa T, Suzuki H, Ito H . Role of chromosomal loss in the progression of prostate cancers. Int J Clin Oncol 2000; 5: 345–354.

    Article  Google Scholar 

  5. Struski S, Doco-Fenzy M, Cornillet-Lefebvre P . Compilation of published comparative genomic hybridization studies. Cancer Genet Cytogenet 2002; 135: 63–90.

    Article  CAS  PubMed  Google Scholar 

  6. Ribeiro FR, Diep CB, Jerónimo C, Henrique R, Lopes C, Eknæs M et al. Statistical discussion of genetic pathways involved in prostate carcinogenesis. Genes Chromosomes Cancer 2006; 45: 154–163.

    Article  CAS  PubMed  Google Scholar 

  7. Suzuki H, Emi M, Komiya A, Fujiwara Y, Yatani R, Nakamura Y et al. Localization of a tumor suppressor gene associated with progression of human prostate cancer within a 1.2 Mb region of 8p22-p21.3. Genes Chromosomes Cancer 1995; 13: 168–174.

    Article  CAS  PubMed  Google Scholar 

  8. Suzuki H, Komiya A, Emi M, Kuramochi H, Shiraishi T, Yatani R et al. Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers. Genes Chromosomes Cancer 1996; 17: 225–233.

    Article  CAS  PubMed  Google Scholar 

  9. Komiya A, Suzuki H, Ueda T, Yatani R, Emi M, Ito H et al. Allelic losses at loci on chromosome 10 are associated with metastasis and progression of human prostate cancer. Genes Chromosomes Cancer 1996; 17: 245–253.

    Article  CAS  PubMed  Google Scholar 

  10. Komiya A, Suzuki H, Ueda T, Aida S, Ito N, Shiraishi T et al. PRLTS gene alterations in human prostate cancer. Jpn J Cancer Res 1997; 88: 389–393.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Kawana Y, Komiya A, Ueda T, Nihei N, Kuramochi H, Suzuki H et al. Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer. Prostate 1997; 32: 205–213.

    Article  CAS  PubMed  Google Scholar 

  12. Kawana Y, Ichikawa T, Suzuki H, Ueda T, Komiya A, Ichikawa Y et al. Loss of heterozygosity at 7q31.1 and 12p13–12 in advanced prostate cancer. Prostate 2002; 53: 60–64.

    Article  CAS  PubMed  Google Scholar 

  13. Ueda T, Komiya A, Emi M, Suzuki H, Shiraishi T, Yatani R et al. Allelic losses on 18q21 are associated with progression and metastasis in human prostate cancer. Genes Chromosomes Cancer 1997; 20: 140–147.

    Article  CAS  PubMed  Google Scholar 

  14. Ueda T, Emi M, Suzuki H, Komiya A, Akakura K, Ichikawa T et al. Identification of a I-cM region of common deletion on 13q14 associated with human prostate cancer. Genes Chromosomes Cancer 1999; 24: 183–190.

    Article  CAS  PubMed  Google Scholar 

  15. Ueda T, Komiya A, Suzuki H, Shimbo M, Sakamoto S, Imamoto T et al. Loss of heterozygosity on chromosome 2 in Japanese patients with prostate cancer. Prostate 2005; 64: 265–271.

    Article  CAS  PubMed  Google Scholar 

  16. Heilporn-Pohl V, Brachet J . Net DNA synthesis in anucleate fragments of Acetabularia mediterranea. Biochim Biophys Acta 1966; 119: 429–431.

    Article  CAS  PubMed  Google Scholar 

  17. Cavalli IJ, Mattevi MS, Erdtmann B, Sbalqueiro IJ, Maia NA . Equivalence of the total constitutive heterochromatin content by an interchromosomal compensation in the C band sizes of chromosomes 1, 9, 16, and Y in Caucasian and Japanese individuals. Hum Hered 1985; 35: 379–387.

    Article  CAS  PubMed  Google Scholar 

  18. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992; 258: 818–821.

    Article  CAS  Google Scholar 

  19. Sun J, Liu W, Adams TS, Sun J, Li X, Turner AR et al. DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. The Prostate 2007; 67: 692–700.

    Article  CAS  PubMed  Google Scholar 

  20. Isola J, DeVries S, Chu L, Ghazvini S, Waldman F . Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Pathol 1994; 145: 1301–1308.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Mckie AB, Douglas DA, Olijslagers S, Graham J, Omar MM, Heer R et al. Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue prostate cancer. Oncogene 2005; 24: 2166–2174.

    Article  CAS  PubMed  Google Scholar 

  22. Bookstein R, Bova GS, MacGrogan D, Levy A, Isaacs WB . Tumour-suppressor genes in prostatic oncogenesis: a positional approach. Br J Urol 1997; 79: 28–36.

    Article  PubMed  Google Scholar 

  23. MacGrogan D, Levy A, Bova GS, Isaacs WB, Bookstein R . Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. Genomics 1996; 35: 55–65.

    Article  CAS  PubMed  Google Scholar 

  24. He WW, Sciavolino PJ, Wing J, Augustus M, Hudson P, Meissner PS et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 1997; 43: 69–77.

    Article  CAS  PubMed  Google Scholar 

  25. Matsui S, LaDuca J, Rossi MR, Nowak NJ, Cowell JK . Molecular characterization of a consistent 4.5-megabase deletion at 4q28 in prostate cancer cells. Cancer Genet Cytogenet 2005; 159: 18–26.

    Article  CAS  PubMed  Google Scholar 

  26. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS et al. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 1996; 56: 3091–3102.

    CAS  PubMed  Google Scholar 

  27. Cooney KA, Wetzel JC, Consolino CM, Wojno KJ . Identification and characterization of proximal 6q deletions in prostate cancer. Cancer Res 1996; 56: 4150–4153.

    CAS  PubMed  Google Scholar 

  28. Srikantan V, Sesterhenn IA, Davis L, Hankins GR, Avallone FA, Livezey JR et al. Allelic loss on chromosome 6Q in primary prostate cancer. Int J Cancer 1999; 84: 331–335.

    Article  CAS  PubMed  Google Scholar 

  29. Hyytinen ER, Saadut R, Chen C, Paull L, Koivisto PA, Vessella RL et al. Defining the region(s) of deletion at 6q16-q22 in human prostate cancer. Genes Chromosomes Cancer 2002; 34: 306–312.

    Article  CAS  PubMed  Google Scholar 

  30. Konishi N, Nakamura M, Kishi M, Ishida E, Shimada K, Matsuyoshi S et al. Genetic mapping of allelic loss on chromosome 6q within heterogeneous prostate carcinoma. Cancer Sci 2003; 94: 764–768.

    Article  CAS  PubMed  Google Scholar 

  31. Phillips JL, Hayward SW, Wang Y, Vasselli J, Pavlovich C, Padilla-Nash H et al. The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res 2001; 61: 8143–8149.

    CAS  PubMed  Google Scholar 

  32. Gorringe KL, Boussioutas A, Bowtell DD, The Melbourne Gastric Cancer Group, Peter Mac Microarray Facility. Novel regions of chromosomal amplification at 6p21, 5p13, and 12q14 in gastric cancer identified by array comparative genomic hybridization. Genes Chromosomes Cancer 2005; 42: 247–259.

    Article  CAS  PubMed  Google Scholar 

  33. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984; 12: 513–516.

    Article  Google Scholar 

  34. Ukita Y, Kato M, Terada T . Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry. J Hepatol 2002; 36: 780–785.

    Article  CAS  PubMed  Google Scholar 

  35. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 245: 177–182.

    Article  Google Scholar 

  36. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC et al. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999; 159: 803–806.

    Google Scholar 

  37. Ribeiro FR, Jerónimo C, Henrique R, Fonseca D, Oliveira J, Lothe RA et al. 8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects. Clin Cancer Res 2006; 12: 3961–3970.

    Article  CAS  PubMed  Google Scholar 

  38. Matsuda K, Matsuyama H, Hara T, Yoshihiro S, Oga A, Kawauchi S et al. DNA sequence copy number aberrations in prostate cancers: a comparison of comparative genomic hybridization data between Japan and European countries. Cancer Genet Cytogenet 2004; 152: 119–123.

    Article  CAS  PubMed  Google Scholar 

  39. Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000; 25: 144–146.

    Article  CAS  PubMed  Google Scholar 

  40. van Duin M, van Marion R, Vissers K, Watson JE, van Weerden WM, Schroder FH et al. High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer. Genes Chromosomes Cancer 2005; 44: 438–449.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Drs Shin-ichiro Niwa and Ayaki Kaneko, Link Genomics Inc., Tokyo, Japan, for their technical support for this study and for their comments during the preparation of this manuscript. The study was supported by Ministry of Education, Culture, Sports, Science and Technology, Japan (Grant numbers: 14207061, 16591582, 16689026, 17791066) and also supported by Yamaguchi Endocrine Research Association (2005, Japan).

Author information

Author notes

  1. S Fukasawa and M Kino: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan

    S Fukasawa, M Kino, M Kobayashi, H Suzuki, A Komiya, T Imamoto & T Ichikawa

  2. Second Department of Pathology, Mie University School of Medicine, Mie, Japan

    Y Hirokawa & T Shiraishi

  3. Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba, Japan

    M Takiguchi

  4. Link Genomics Inc., Tokyo, Japan

    H Ishida & T Shindo

  5. Department of Functional Genomics, Graduate School of Medicine, Chiba University, Chiba, Japan

    N Seki

Authors
  1. S Fukasawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Kino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Komiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Imamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Y Hirokawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T Shiraishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Takiguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H Ishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. T Shindo
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. N Seki
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. T Ichikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Ichikawa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fukasawa, S., Kino, M., Kobayashi, M. et al. Genetic changes in pT2 and pT3 prostate cancer detected by comparative genomic hybridization. Prostate Cancer Prostatic Dis 11, 303–310 (2008). https://doi.org/10.1038/sj.pcan.4501017

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4501017

Keywords

This article is cited by

Search

Advanced search

Quick links